A Phase 2 interventional study of MC2-01 Cream and CAL/BDP combination in Psoriasis Vulgaris, sponsored by MC2 Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-24.
Sponsored by MC2 Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.
Among the 47 studies testing calcipotriene in Psoriasis, this one is the 30th largest by enrollment, is one of 3 that started in 2018, is one of 9 in phase 2, and was the 35th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 19 · Phase 4 12
First in 2004; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 200 across the 47 interventional studies. Of the 41 that completed or were terminated, 21 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 47 have an industry lead sponsor. The 10 most frequent:
MC2 Therapeutics is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.
MC2 Therapeutics has 4 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing calcipotriene in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 2, randomised, open-label, parallel-group, multicentre trial in which MC2-01 cream and calcipotriene [CAL]/betamethasone [BDP] ointment (comparator) is investigated in subjects with clinically diagnosed extensive psoriasis vulgaris.
The MC2-01 cream is designed for optimal patient satisfaction - it quickly absorbs into the skin leaving it nicely moisturized allowing patients to move on with daily routines. In this trial, the MC2-01 cream will be compared to a marketed calcipotriene [CAL]/betamethasone dipropionate [BDP] ointment. The purpose of the trial, is to determine the pharmacokinetic parameters of MC2-01 cream and the comparator under maximum use conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MC2-01 cream (CAL and BDP, w/w 0.005%/ 0.064%).
Drug: MC2-01 Cream
CAL/BDP ointment (w/w 0.005%/0.064%).
Drug: CAL/BDP combination
Drug pages: Calcipotriene · Betamethasone dipropionate
MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)
Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)
Maximum Plasma Concentration (Cmax) of the Active Ingredient Calcipotriene
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Calcipotriene. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
Time frame: Week 4
Maximum Plasma Concentration (Cmax) of the Active Ingredient Calcipotriene
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Calcipotriene. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
Time frame: Week 8
Maximum Plasma Concentration (Cmax) of Active Ingredient Betamethasone Dipropionate
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Betamethasone Dipropionate. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
Time frame: Week 4
Maximum Plasma Concentration (Cmax) of Active Ingredient Betamethasone Dipropionate
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Betamethasone Dipropionate. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
Time frame: Week 8
Maximum Plasma Concentration (Cmax) of the Metabolite MC1080
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the metabolite MC1080. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
Time frame: Week 4
Maximum Plasma Concentration (Cmax) of the Metabolite MC1080
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the metabolite MC1080. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
Time frame: Week 8
Maximum Plasma Concentration (Cmax) of Metabolite Betamethasone 17-propionate
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the metabolite Betamethasone 17-propionate. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
Time frame: Week 4
Maximum Plasma Concentration (Cmax) of Metabolite Betamethasone 17-propionate
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the metabolite Betamethasone 17-propionate. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
Time frame: Week 8
Number of Subjects With Hypothalamic-pituitary-adrenal [HPA] Suppression After 4 Weeks of Treatment
The HPA axis evaluation is based on an Adrenocorticotropic hormone \[ACTH\] challenge test, defined by a 30 minutes ACTH stimulated cortisol value. Only subject with no HPA suppression at baseline were included in the analysis. The outcome measure lists the number of subjects with HPA suppression 30 minutes after ACTH challenge
Time frame: Week 4
Number of Subjects With Hypothalamic-pituitary-adrenal [HPA] Suppression After 8 Weeks of Treatment
The HPA challenge test were only performed on subjects that were assigned to the MC2-01 cream group. Out of a total of 32 subjects, 5 subjects were excluded from the analysis as they had HPA suppression at baseline
Time frame: Week 8
Calcium Metabolism Evaluation in Albumin-corrected Serum Calcium
Changes from baseline of albumin-corrected serum calcium \[mmol/L\]
Time frame: Baseline and week 4
Calcium Metabolism Evaluation in Albumin-corrected Serum Calcium
Changes from baseline in albumin-corrected serum calcium \[mmol/L\]
Time frame: Baseline and week 8
Calcium Metabolism Evaluation of 24-hour Urinary Calcium Excretion
Changes from baseline of 24-hour urinary calcium excretion \[mmol/day\]
Time frame: Baseline and week 4
Calcium Metabolism Evaluation of 24-hour Urinary Calcium Excretion
Changes from baseline of 24-hour urinary calcium excretion \[mmol/day\]
Time frame: Baseline and week 8
Calcium Metabolism Evaluation of the Ratio of Urinary Calcium to Creatinine
Changes from baseline in ratio of urinary calcium to creatinine defined as urinary calcium (mmol)/creatinine (g)
Time frame: Baseline and week 4
Calcium Metabolism Evaluation of the Ratio of Urinary Calcium to Creatinine
Changes from baseline in ratio of urinary calcium to creatinine defined as urinary calcium (mmol)/creatinine (g)
Time frame: Baseline and week 8
First Subject First Visit: 08Feb-2018. Last Subject Last Visit: 04-Aug-2018.
| Milestone | MC2-01 Cream | CAL/BDP Combination |
|---|---|---|
| Started | 32 | 31 |
| Completed | 26 | 29 |
| Not completed | 6 | 2 |
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Calcipotriene. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
| pg/mL | MC2-01 Cream | CAL/BDP Ointment |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of the Active Ingredient Calcipotriene | 30.2 (29.8 to 30.7) | 30.0 (30 to 30) |
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Calcipotriene. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
| pg/mL | MC2-01 Cream |
|---|---|
| Maximum Plasma Concentration (Cmax) of the Active Ingredient Calcipotriene | 30.0 (30.0 to 30.0) |
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Betamethasone Dipropionate. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
| pg/mL | MC2-01 Cream | CAL/BDP Combination |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of Active Ingredient Betamethasone Dipropionate | 21.5 (19.5 to 23.7) | 23.1 (19.0 to 28.1) |
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Betamethasone Dipropionate. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
| pg/mL | MC2-01 Cream |
|---|---|
| Maximum Plasma Concentration (Cmax) of Active Ingredient Betamethasone Dipropionate | 20.0 (20.0 to 20.0) |
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the metabolite MC1080. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
| pg/mL | MC2-01 Cream | CAL/BDP Ointment |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of the Metabolite MC1080 | 29.8 (28.7 to 31.0) | 29.2 (29.0 to 29.3) |
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the metabolite MC1080. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
| pg/mL | MC2-01 Cream |
|---|---|
| Maximum Plasma Concentration (Cmax) of the Metabolite MC1080 | 29.1 (29.1 to 29.1) |
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the metabolite Betamethasone 17-propionate. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
| pg/mL | MC2-01 Cream | CAL/BDP Ointment |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of Metabolite Betamethasone 17-propionate | 39.3 (25.8 to 59.8) | 38.2 (27.4 to 53.4) |
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the metabolite Betamethasone 17-propionate. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
| pg/mL | MC2-01 Cream |
|---|---|
| Maximum Plasma Concentration (Cmax) of Metabolite Betamethasone 17-propionate | 26.2 (20.5 to 33.5) |
The HPA axis evaluation is based on an Adrenocorticotropic hormone \[ACTH\] challenge test, defined by a 30 minutes ACTH stimulated cortisol value. Only subject with no HPA suppression at baseline were included in the analysis. The outcome measure lists the number of subjects with HPA suppression 30 minutes after ACTH challenge
| Participants | MC2-01 Cream |
|---|---|
| Number of Subjects With Hypothalamic-pituitary-adrenal [HPA] Suppression After 4 Weeks of Treatment | 1 |
The HPA challenge test were only performed on subjects that were assigned to the MC2-01 cream group. Out of a total of 32 subjects, 5 subjects were excluded from the analysis as they had HPA suppression at baseline
| Participants | MC2-01 Cream |
|---|---|
| Number of Subjects With Hypothalamic-pituitary-adrenal [HPA] Suppression After 8 Weeks of Treatment | 2 |
Changes from baseline of albumin-corrected serum calcium \[mmol/L\]
| mmol/L | MC2-01 Cream |
|---|---|
| Calcium Metabolism Evaluation in Albumin-corrected Serum Calcium | -0.00 ± 0.09 |
Changes from baseline in albumin-corrected serum calcium \[mmol/L\]
| mmol/L | MC2-01 Cream |
|---|---|
| Calcium Metabolism Evaluation in Albumin-corrected Serum Calcium | 0.00 ± 0.07 |
Changes from baseline of 24-hour urinary calcium excretion \[mmol/day\]
| mmol/day | MC2-01 Cream |
|---|---|
| Calcium Metabolism Evaluation of 24-hour Urinary Calcium Excretion | -0.56 ± 1.69 |
Changes from baseline of 24-hour urinary calcium excretion \[mmol/day\]
| mmol/day | MC2-01 Cream |
|---|---|
| Calcium Metabolism Evaluation of 24-hour Urinary Calcium Excretion | -0.45 ± 1.08 |
Changes from baseline in ratio of urinary calcium to creatinine defined as urinary calcium (mmol)/creatinine (g)
| mmol/g | MC2-01 Cream |
|---|---|
| Calcium Metabolism Evaluation of the Ratio of Urinary Calcium to Creatinine | -0.23 ± 1.49 |
Changes from baseline in ratio of urinary calcium to creatinine defined as urinary calcium (mmol)/creatinine (g)
| mmol/g | MC2-01 Cream |
|---|---|
| Calcium Metabolism Evaluation of the Ratio of Urinary Calcium to Creatinine | 0.00 ± 1.32 |
Collected over AEs were collected/assessed from the time of the signature of the informed consent form by the subject during the screening visit (up to 4 weeks prior to treatment), during the treatment period (up to 8 weeks) and until the final follow-up visit had occurred (up to 4 weeks following end of treatment). All AEs that were considered related to the trial product would be followed until they were resolved, or until the medical condition of the subject was stable. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MC2-01 Cream | 0/32 (0%) | 0/32 (0%) | 0/32 (0%) |
| CAL/BDP Combination | 0/31 (0%) | 1/31 (3.2%) | 0/31 (0%) |
| Event | MC2-01 Cream | CAL/BDP Combination |
|---|---|---|
| Ankle FractureMusculoskeletal and connective tissue disorders | 0/32 | 1/31 |
| Age, Continuous(years) | MC2-01 Cream | CAL/BDP Combination | Total |
|---|---|---|---|
| Mean | 52.8 ± 15.5 | 49.7 ± 16.2 | 51.3 ± 15.8 |
| Sex: Female, Male(Participants) | MC2-01 Cream | CAL/BDP Combination | Total |
|---|---|---|---|
| Female | 19 | 21 | 40 |
| Male | 13 | 10 | 23 |
| Race (NIH/OMB)(Participants) | MC2-01 Cream | CAL/BDP Combination | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 28 | 28 | 56 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | MC2-01 Cream | CAL/BDP Combination | Total |
|---|---|---|---|
| United States | 32 | 31 | 63 |
| Baseline Physician's Global Assessment (PGA)(Participants) | MC2-01 Cream | CAL/BDP Combination | Total |
|---|---|---|---|
| Moderate | 29 | 30 | 59 |
| Severe | 3 | 1 | 4 |
| Baseline Body Surface Area (BSA)(Percentage of psoriasis involvement) | MC2-01 Cream | CAL/BDP Combination | Total |
|---|---|---|---|
| Mean | 23.56 ± 2.52 | 24.09 ± 3.13 | 23.82 ± 2.82 |
| Fitzpatrick Skin Type(Participants) | MC2-01 Cream | CAL/BDP Combination | Total |
|---|---|---|---|
| I | 3 | 2 | 5 |
| II | 11 | 9 | 20 |
| III | 8 | 6 | 14 |
| IV | 5 | 9 | 14 |
| V | 3 | 5 | 8 |
| VI | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2018 to primary completion in Aug 2018, 5 months.
Results were first posted in Dec 2019, 1 year 4 months after primary completion.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 5 months is below that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate
MC2 Therapeutics